Compass Therapeutics Inc. announced a business update highlighting progress across its clinical-stage pipeline. The company reported an estimated $209 million in cash and marketable securities as of December 31, 2025, expected to provide a cash runway into 2028. The company remains on track to report analyses of progression-free survival $(PFS)$ and overall survival $(OS)$ in late Q1 2026 from the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer. In the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), a third response has been confirmed in a patient with Hodgkin Lymphoma, and a previously disclosed deep partial response in a patient with triple negative breast cancer is now durable through week 32. Cohort expansions for CTX-8371 are now open for triple negative breast cancer and non-small cell lung cancer patients. A Phase 1 study of CTX-10726 (PD-1 x VEGF-A bispecific antibody) is expected to begin in Q1 2026, with initial data anticipated in the second half of 2026. Data from tovecimig’s Phase 2 study in colorectal cancer will be presented at the 2026 ASCO GI Cancers Symposium, with the drug previously demonstrating monotherapy activity in heavily pretreated metastatic colorectal cancer patients. Compass Therapeutics also announced the appointment of Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9620240) on January 06, 2026, and is solely responsible for the information contained therein.